leisure time -WSS

leisure time

author：fashion 2025-09-27 09:53:40 - browse：9992

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： What AstraZeneca

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

When prostate cancer spreads, where it goes matters

Teacher posts viral 'school supply rant' with advice for parents

HCA says smaller share of spending going to labor

5 wounded, 2 critically, in Michigan shopping center shooting

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Wikipedia

leisure time

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Arc Institute generative AI designs new CRISPR systems

Cancer drug shortages should be causing more outrage

Teacher posts viral 'school supply rant' with advice for parents

Walensky prepares to leave CDC — and Congress — behind

5 wounded, 2 critically, in Michigan shopping center shooting

Psychedelics group wrestles with new pharma identity

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Bright Health sells Medicare Advantage business to Molina

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

Addiction experts warn against a second 'war on drugs'

'Weather

5 wounded, 2 critically, in Michigan shopping center shooting

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

What AstraZeneca

Data integrity in scientific journals requires "effort" by publishers, institutions

focus

hotspot

explore

Wikipedia